Drug Utilization Review Board
Meeting Agenda
Thursday, February 12, 2026
7:15 a.m. to 8:30 a.m.
Google Meet joining info Video call link: meet.google.com/qbv-rjpz-fst
Or dial: (US) +1 314-474-3014 PIN: 334 496 072#
Persons who wish to address the DUR Board may contact Luis Moreno at lmoreno@utah.gov at least 48 hours prior to the meeting. Public comments will be limited to 3 minutes per speaker or organization due to time constraints.
1) Call to order - Sharon Weinstein, MD
a) Welcome
b) Review and Approval of Minutes
2) Housekeeping - Luis Moreno, PharmD
3) Prior Authorization Updates - Luis Moreno, PharmD
4) Public Comment
5) Review New Prior Authorization Criteria
a) Javygtor, Kuvan, Zelvysia (sapropterin) - Kyu Yun Park, PharmD
i) Committee Discussion/Questions
ii) Committee Action
b) Encelto (revakinagene taroretcel) for macular talangiectasia type 2 - Iris Wan, PharmD
i) Committee Discussion/Questions
ii) Committee Action
c) Enspryng (satralizumab-mwge) - Luis Moreno, PharmD
i) Committee Discussion/Questions
ii) Committee Action
d) Palynziq (pegvaliase-pqpz) - Skylar Fenton, PharmD
i) Committee Discussion/Questions
ii) Committee Action
6) Next Meeting
a) Date: March 12, 2026
b) Topic: GLP-1 Receptor Agonists Approved for Weight Management (liraglutide, semaglutide, and tirzepatide)
7) Adjourned - Sharon Weinstein, MD
Notice of Special Accommodations (ADA)
In compliance with the Americans with Disabilities Act, individuals needing special accommodations (including auxiliary communicative aids and services) during this meeting should notify Luis Moreno at 801-538-6155.
Notice of Electronic or Telephone Participation
Google Meet joining info Video call link: meet.google.com/qbv-rjpz-fst
Or dial: (US) +1 314-474-3014 PIN: 334 496 072#